EBS Technologies is a privately held life science company located near Berlin, Germany that developed a non-invasive, patient-individualized electrical stimulation therapy to restore vision impairments caused by neurological disorders such as glaucoma, stroke, brain injury, or eye infarct. The treatment application creates a personalized electrical stimulation to individually address the patient’s disposition during the 10 day treatment. Currently, EBS is commercializing the NEXT WAVE™ therapy in cooperation with clinical centers in Germany, other countries to follow. A solid portfolio of currently 9 patent families protects EBS innovations. The CE-marked technology has already demonstrated its effectiveness by an evidence class I b trial. With an average improvement of 24% of the whole visual field, there is no therapeutic alternative today.
Dr. Karl Schweitzer